vs

Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Essex Property Trust (ESS). Click either name above to swap in a different company.

CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $479.6M, roughly 1.0× Essex Property Trust). Essex Property Trust runs the higher net margin — 17.9% vs -10.1%, a 28.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs 5.5%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 6.0%).

Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.

Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.

CLOV vs ESS — Head-to-Head

Bigger by revenue
CLOV
CLOV
1.0× larger
CLOV
$487.7M
$479.6M
ESS
Growing faster (revenue YoY)
CLOV
CLOV
+39.2% gap
CLOV
44.7%
5.5%
ESS
Higher net margin
ESS
ESS
28.0% more per $
ESS
17.9%
-10.1%
CLOV
Faster 2-yr revenue CAGR
CLOV
CLOV
Annualised
CLOV
18.6%
6.0%
ESS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CLOV
CLOV
ESS
ESS
Revenue
$487.7M
$479.6M
Net Profit
$-49.3M
$85.7M
Gross Margin
70.0%
Operating Margin
-10.1%
31.7%
Net Margin
-10.1%
17.9%
Revenue YoY
44.7%
5.5%
Net Profit YoY
-123.2%
-71.6%
EPS (diluted)
$1.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLOV
CLOV
ESS
ESS
Q4 25
$487.7M
$479.6M
Q3 25
$496.6M
$473.3M
Q2 25
$477.6M
$469.8M
Q1 25
$462.3M
$464.6M
Q4 24
$337.0M
$454.5M
Q3 24
$331.0M
$450.7M
Q2 24
$356.3M
$442.4M
Q1 24
$346.9M
$426.9M
Net Profit
CLOV
CLOV
ESS
ESS
Q4 25
$-49.3M
$85.7M
Q3 25
$-24.4M
$172.7M
Q2 25
$-10.6M
$231.5M
Q1 25
$-1.3M
$212.8M
Q4 24
$-22.1M
$301.7M
Q3 24
$-9.2M
$125.5M
Q2 24
$7.4M
$99.0M
Q1 24
$-19.2M
$285.1M
Gross Margin
CLOV
CLOV
ESS
ESS
Q4 25
70.0%
Q3 25
69.2%
Q2 25
70.7%
Q1 25
69.6%
Q4 24
70.0%
Q3 24
24.5%
69.5%
Q2 24
30.3%
70.8%
Q1 24
23.6%
69.7%
Operating Margin
CLOV
CLOV
ESS
ESS
Q4 25
-10.1%
31.7%
Q3 25
-4.9%
44.5%
Q2 25
-2.2%
59.5%
Q1 25
-0.3%
55.3%
Q4 24
-6.4%
67.0%
Q3 24
-2.7%
28.6%
Q2 24
2.0%
31.1%
Q1 24
-6.5%
31.0%
Net Margin
CLOV
CLOV
ESS
ESS
Q4 25
-10.1%
17.9%
Q3 25
-4.9%
36.5%
Q2 25
-2.2%
49.3%
Q1 25
-0.3%
45.8%
Q4 24
-6.6%
66.4%
Q3 24
-2.8%
27.8%
Q2 24
2.1%
22.4%
Q1 24
-5.5%
66.8%
EPS (diluted)
CLOV
CLOV
ESS
ESS
Q4 25
$1.24
Q3 25
$2.56
Q2 25
$3.44
Q1 25
$3.16
Q4 24
$4.00
Q3 24
$1.84
Q2 24
$1.45
Q1 24
$4.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLOV
CLOV
ESS
ESS
Cash + ST InvestmentsLiquidity on hand
$78.3M
$76.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$308.7M
$5.5B
Total Assets
$541.0M
$13.2B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLOV
CLOV
ESS
ESS
Q4 25
$78.3M
$76.2M
Q3 25
$66.0M
Q2 25
$58.7M
Q1 25
$98.7M
Q4 24
$194.5M
$66.8M
Q3 24
$288.0M
$71.3M
Q2 24
$254.8M
$55.2M
Q1 24
$208.3M
$499.0M
Total Debt
CLOV
CLOV
ESS
ESS
Q4 25
Q3 25
$6.4B
Q2 25
$6.4B
Q1 25
$6.8B
Q4 24
Q3 24
$6.4B
Q2 24
$6.2B
Q1 24
$6.6B
Stockholders' Equity
CLOV
CLOV
ESS
ESS
Q4 25
$308.7M
$5.5B
Q3 25
$340.9M
$5.6B
Q2 25
$344.2M
$5.6B
Q1 25
$336.1M
$5.6B
Q4 24
$341.1M
$5.5B
Q3 24
$342.2M
$5.4B
Q2 24
$324.9M
$5.5B
Q1 24
$292.5M
$5.5B
Total Assets
CLOV
CLOV
ESS
ESS
Q4 25
$541.0M
$13.2B
Q3 25
$559.7M
$13.2B
Q2 25
$575.0M
$13.2B
Q1 25
$583.7M
$13.2B
Q4 24
$580.7M
$12.9B
Q3 24
$653.0M
$12.6B
Q2 24
$674.2M
$12.5B
Q1 24
$671.8M
$12.9B
Debt / Equity
CLOV
CLOV
ESS
ESS
Q4 25
Q3 25
1.15×
Q2 25
1.14×
Q1 25
1.22×
Q4 24
Q3 24
1.18×
Q2 24
1.13×
Q1 24
1.19×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLOV
CLOV
ESS
ESS
Operating Cash FlowLast quarter
$-66.9M
$1.1B
Free Cash FlowOCF − Capex
$-69.0M
FCF MarginFCF / Revenue
-14.1%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
12.53×
TTM Free Cash FlowTrailing 4 quarters
$-69.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLOV
CLOV
ESS
ESS
Q4 25
$-66.9M
$1.1B
Q3 25
$12.1M
$342.6M
Q2 25
$5.4M
$216.1M
Q1 25
$-16.3M
$281.5M
Q4 24
$34.8M
$1.1B
Q3 24
$50.0M
$316.2M
Q2 24
$44.8M
$218.9M
Q1 24
$25.9M
$314.9M
Free Cash Flow
CLOV
CLOV
ESS
ESS
Q4 25
$-69.0M
Q3 25
$11.4M
Q2 25
$4.8M
Q1 25
$-16.5M
Q4 24
$33.3M
Q3 24
$49.6M
Q2 24
$44.4M
Q1 24
$25.5M
FCF Margin
CLOV
CLOV
ESS
ESS
Q4 25
-14.1%
Q3 25
2.3%
Q2 25
1.0%
Q1 25
-3.6%
Q4 24
9.9%
Q3 24
15.0%
Q2 24
12.5%
Q1 24
7.3%
Capex Intensity
CLOV
CLOV
ESS
ESS
Q4 25
0.4%
Q3 25
0.1%
Q2 25
0.1%
Q1 25
0.0%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
CLOV
CLOV
ESS
ESS
Q4 25
12.53×
Q3 25
1.98×
Q2 25
0.93×
Q1 25
1.32×
Q4 24
3.54×
Q3 24
2.52×
Q2 24
6.04×
2.21×
Q1 24
1.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons